naproxen has been researched along with ketotifen in 7 studies
Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (ketotifen) | Trials (ketotifen) | Recent Studies (post-2010) (ketotifen) |
---|---|---|---|---|---|
4,551 | 1,057 | 1,429 | 1,212 | 275 | 151 |
Protein | Taxonomy | naproxen (IC50) | ketotifen (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.16 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.838 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.009 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.374 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.187 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.112 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.71 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 2.537 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 2.209 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.872 | |
Histamine H2 receptor | Homo sapiens (human) | 4.129 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 3.727 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.031 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.16 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 2.537 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0011 | |
D(3) dopamine receptor | Homo sapiens (human) | 1.963 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.046 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.141 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Strassburg, CP; Tukey, RH | 1 |
Chang, TK; Ensom, MH; Kiang, TK | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Dahl, TA; Iversen, JM; Kiani, P; McMann, L; Scholey, A; Verster, JC | 1 |
2 review(s) available for naproxen and ketotifen
Article | Year |
---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
5 other study(ies) available for naproxen and ketotifen
Article | Year |
---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytopathogenic Effect, Viral; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Humans; Indomethacin; Ketotifen; Naproxen; SARS-CoV-2 | 2021 |